Volume 9, Number 10—October 2003
Research
Superantigens and Streptococcal Toxic Shock Syndrome
Table
Serum |
Isolate |
Focus |
spe-a |
SPE-A |
sag gene/SAg protein production |
SMEZc |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
spe-c |
SPE-C |
spe-g |
SPE-G |
spe-h |
SPE-H |
spe-i |
SPE-I |
spe-j |
SPE-J |
smez |
SMEZ |
ssa |
SSA |
|||||||
Focal infection/bacteremia with STSS | ||||||||||||||||||||
94/31 |
H292 |
Fasciitis |
- |
- |
- |
- |
+ |
- |
+ |
- |
+ |
++ |
+ |
- |
+ |
- |
- |
- |
+ |
|
95/02 |
H293 |
Fasciitis |
- |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
++ |
|
96/2 |
H297 |
Peritonitis |
+ |
- |
- |
- |
+ |
++ |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
+ |
|
98/5 |
H325 |
Fasciitis |
+ |
+++ |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
- |
+ |
- |
+ |
- |
+ |
|
98/8 |
H327 |
Cellulitis |
- |
- |
- |
- |
+ |
+ |
- |
- |
- |
- |
+ |
- |
+ |
_ |
+ |
+ |
- |
|
98/11 |
H330 |
Endometritis |
+ |
+++ |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
+ |
- |
+ |
|
99/1 |
H360 |
Occult bact. |
- |
- |
+ |
+ |
+ |
+ |
- |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
++ |
|
99/18 |
H366 |
Pneumonia |
+ |
+++ |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
++ |
+ |
- |
- |
- |
+ |
|
20/07 |
H378 |
Pneumonia |
- |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
+ |
- |
+ |
- |
+ |
- |
+ |
|
Focal infection/bacteremia, no STSS |
||||||||||||||||||||
95/8 |
H295 |
Cellulitis |
- |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
+++ |
+ |
- |
- |
- |
++ |
|
98/1 |
H319 |
Cellulitis |
- |
- |
- |
- |
+ |
++ |
- |
- |
- |
- |
+ |
++ |
+ |
- |
- |
- |
++ |
|
20/01 |
H369 |
Pelvic clot |
- |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
+++ |
|
20/04 |
H370 |
Thromobosis |
- |
- |
- |
- |
+ |
+ |
- |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
- |
|
Focal infection, no bacteremia, no STSS |
||||||||||||||||||||
97/15 |
H307 |
Bursitis |
- |
- |
+ |
+++ |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
+ |
|
97/18 |
H308 |
Cellulitis |
+ |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
+ |
- |
+ |
- |
+ |
- |
- |
|
97/21 |
H311 |
Cellulitis |
- |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
- |
+ |
- |
- |
- |
+ |
|
97/23 |
H314 |
Cellulitis |
+ |
- |
- |
- |
+ |
+ |
+ |
- |
+ |
- |
+ |
+ |
+ |
- |
- |
- |
++ |
|
97/24 |
H315 |
Cellulitis |
+ |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
|
97/26 | H316 | Amnionitis | - | - | + | +++ | + | + | - | - | - | - | + | ++ | + | - | + | - | - |
aSAg, superantigen; SPE, streptococcal pyrogenic exotoxin; SME, streptococcal mitogenic exotoxin; STSS, streptococcal toxic shock syndrome.
bS. pyogenes isolates from patients with and without STSS were genotyped by polymerase chain reaction with sag specific primers. Concentrated supernatant from the in vitro cultured isolates were analyzed for secreted SAgs by using Western blot analysis with recombinant SAg standards. SMEZ expression was also analyzed by using the more sensitive Jurkat cell assay, which has a threshold of approximately 10 pg/mL. SAg expression by Western blot: -, no detectable protein; +, <2 ng/mL; ++, 2–10 ng/mL; +++, >10 ng/mL. SMEZ expression by Jurkat assay: -, no detectable SMEZ; +, >10 pg/ml (10,000–20,000 cpm); ++, 20,000–30,000 cpm; +++, >30,000 cpm.
cJurkat assay.